日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

瑞戈非尼联合FOLFOX或FOLFIRI方案作为结直肠癌一线或二线治疗：一项多中心Ib期研究的结果

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdt056
Schultheis, B; Folprecht, G; Kuhlmann, J; Ehrenberg, R; Hacker, U T; Köhne, C H; Kornacker, M; Boix, O; Lettieri, J; Krauss, J; Fischer, R; Hamann, S; Strumberg, D; Mross, K B
肿瘤
肠癌
肿瘤免疫
发表日期：2013
文献求助 收藏

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

一项针对未经化疗的不可切除胰腺外分泌腺癌患者的随机II期试验，评估Polo样激酶抑制剂BI 2536的疗效——该研究隶属于中欧抗癌药物研究学会（CESAR）合作网络。

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/bjc.2012.257
Mross, K; Dittrich, C; Aulitzky, W E; Strumberg, D; Schutte, J; Schmid, R M; Hollerbach, S; Merger, M; Munzert, G; Fleischer, F; Scheulen, M E
信号转导
肿瘤
药物研究
肿瘤免疫
发表日期：2012
文献求助 收藏

Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours

Plk1抑制剂BI 2536在晚期实体瘤中连续三天静脉注射的I期研究

期刊:Current Oncology
影响因子:3.4
doi:10.3747/co.19.866
Frost, A; Mross, K; Steinbild, S; Hedbom, S; Unger, C; Kaiser, R; Trommeshauser, D; Munzert, G
发表日期：2012
文献求助 收藏

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.

特拉替尼（BAY 57-9352）治疗晚期实体瘤患者的 I 期剂量递增研究

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/sj.bjc.6604724
Strumberg D, Schultheis B, Adamietz I A, Christensen O, Buechert M, Kraetzschmar J, Rajagopalan P, Ludwig M, Frost A, Steinbild S, Scheulen M E, Mross K
肿瘤
肿瘤免疫
发表日期：2008
文献求助 收藏

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

一项针对进展期激素难治性前列腺癌患者的索拉非尼II期临床研究：CESAR中欧抗癌药物研究学会-EWIV研究

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/sj.bjc.6604064
Steinbild, S; Mross, K; Frost, A; Morant, R; Gillessen, S; Dittrich, C; Strumberg, D; Hochhaus, A; Hanauske, A-R; Edler, L; Burkholder, I; Scheulen, M
肿瘤
药物研究
肿瘤免疫
前列腺癌
免疫/内分泌
发表日期：2007
文献求助 收藏

Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer

右维拉帕米和表柔比星治疗难治性转移性乳腺癌患者的II期临床试验

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/bjc.1998.192
Lehnert, M; Mross, K; Schueller, J; Thuerlimann, B; Kroeger, N; Kupper, H
肿瘤
肿瘤免疫
乳腺癌
发表日期：1998
文献求助 收藏

Reverse transcriptase/polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients

采用逆转录/聚合酶链式反应检测乳腺癌患者骨髓和血液中细胞角蛋白-19 mRNA

期刊:Journal of Cancer Research and Clinical Oncology
影响因子:2.8
doi:10.1007/BF01209032
Krüger, W; Krzizanowski, C; Holweg, M; Stockschläder, M; Kröger, N; Jung, R; Mross, K; Jonat, W; Zander, A R
肿瘤
肿瘤免疫
乳腺癌
细胞生物学
PCR
发表日期：1996
文献求助 收藏

Dexverapamil to overcome epirubicin resistance in advanced breast cancer

右维拉帕米可克服晚期乳腺癌的表柔比星耐药性

期刊:Journal of Cancer Research and Clinical Oncology
影响因子:2.8
doi:10.1007/BF02351063
Thürlimann, B; Kröger, N; Greiner, J; Mross, K; Schüller, J; Schernhammer, E; Schumacher, K; Gastl, G; Hartlapp, J; Kupper, H
肿瘤
肿瘤免疫
乳腺癌
发表日期：1995
文献求助 收藏